Japan Readies One-Off Price Cuts For Big Sellers
Entresto Slashed By 15%
Japanese regulatory authorities have announced a set of additional reimbursement price cuts for selected products in August, under which Novartis’s heart failure drug Entresto will see its price slashed by 15%. A batch of other newly approved drugs has also been priced.
